array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2751) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(63) "Exploring Regeneron's Future: Innovations and Market Strategies" ["snippet_en"]=> string(147) "Discover the innovative strategies and market challenges faced by Regeneron Pharmaceuticals as it seeks to enhance growth and navigate competition." ["url"]=> string(98) "https://investorshangout.com/exploring-regenerons-future-innovations-and-market-strategies-46733-/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5e6fb2c2-1996-4025-8d52-9513e6fe7118" ["source"]=> string(20) "investorshangout.com" ["publication_date"]=> string(10) "2024-09-30" ["categories"]=> array(4) { [0]=> string(15) "Market Movement" [1]=> string(21) "Competitive Behaviour" [2]=> string(5) "R & D" [3]=> string(11) "Competition" } } [1]=> array(7) { ["title_en"]=> string(111) "Fed­er­al judge rules against Re­gen­eron's at­tempt to halt Am­gen from launch­ing Eylea biosim­i­lar" ["snippet_en"]=> string(301) "Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its blockbuster eye treatment Eylea. While Regeneron previously defended itself in court from imminent competition, the US District Court for the Northern District of West Virginia" ["url"]=> string(76) "https://endpts.com/regeneron-hits-setback-in-eylea-patent-battle-with-amgen/" ["image_url"]=> NULL ["source"]=> string(10) "endpts.com" ["publication_date"]=> string(10) "2024-09-25" ["categories"]=> array(5) { [0]=> string(21) "Competitive Behaviour" [1]=> string(5) "Legal" [2]=> string(10) "Litigation" [3]=> string(8) "Verdicts" [4]=> string(12) "Stock Market" } } [2]=> array(7) { ["title_en"]=> string(38) "Legal Lens on the Unified Patent Court" ["snippet_en"]=> string(190) "The Unified Patent Court (UPC) is revolutionizing the way patents are enforced in Europe, and McDermott’s intellectual property team is here to help you navigate this dynamic landscape...." ["url"]=> string(81) "https://www.jdsupra.com/legalnews/legal-lens-on-the-unified-patent-court-9286045/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bf0f869d-23c7-46f1-80e7-1401254eded4" ["source"]=> string(11) "jdsupra.com" ["publication_date"]=> string(10) "2024-08-29" ["categories"]=> array(4) { [0]=> string(21) "Competitive Behaviour" [1]=> string(5) "Legal" [2]=> string(21) "Intellectual Property" [3]=> string(8) "Verdicts" } } [3]=> array(7) { ["title_en"]=> string(104) "Do intellectual property rights hinder or promote vaccine development? Doctors Without Borders tells you" ["snippet_en"]=> string(106) "Myth: Intellectual property rights enable breakthroughs in the development of COVID-19 drugs and vaccines." ["url"]=> string(38) "https://www.coolloud.org.tw/node/95865" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6271f580-5986-4c05-a5b8-32b6ce02699c" ["source"]=> string(15) "coolloud.org.tw" ["publication_date"]=> string(10) "2024-03-04" ["categories"]=> array(6) { [0]=> string(14) "Product Launch" [1]=> string(21) "Competitive Behaviour" [2]=> string(11) "Competition" [3]=> string(24) "Access and affordability" [4]=> string(21) "Intellectual Property" [5]=> string(8) "Epidemic" } } [4]=> array(7) { ["title_en"]=> string(90) "Regeneron Pharmaceuticals (REGN): Porter’s Five Forces Industry and Competition Analysis" ["snippet_en"]=> string(148) "Regeneron Pharmaceuticals faces the challenge of sustaining its competitive edge amidst intense industry rivalry and evolving regulatory landscapes." ["url"]=> string(116) "https://www.hivelr.com/2024/02/regeneron-pharmaceuticals-regn-porters-five-forces-industry-and-competition-analysis/" ["image_url"]=> NULL ["source"]=> string(10) "hivelr.com" ["publication_date"]=> string(10) "2024-02-29" ["categories"]=> array(7) { [0]=> string(14) "Product Launch" [1]=> string(5) "R & D" [2]=> string(15) "Market Movement" [3]=> string(25) "Business Model Resilience" [4]=> string(21) "Competitive Behaviour" [5]=> string(11) "Competition" [6]=> string(13) "Collaboration" } } [5]=> array(7) { ["title_en"]=> string(48) "Wall Street Comments on Uber, Lyft and Regeneron" ["snippet_en"]=> string(167) "Nomura downgraded Uber (NYSE:UBER) shares to neutral buy, raising their target price to $62 from $59, DKNews.kz reports. The firm believes the company's shares are now" ["url"]=> string(85) "https://dknews.kz/ru/biznes/312002-kommentarii-na-uoll-strit-po-uber-lyft-i-regeneron" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c73af0e3-5210-440f-8b55-8705c2a06d9a" ["source"]=> string(9) "dknews.kz" ["publication_date"]=> string(10) "2024-01-01" ["categories"]=> array(9) { [0]=> string(46) "Management of Legal and Regulatory Environment" [1]=> string(21) "Competitive Behaviour" [2]=> string(5) "Legal" [3]=> string(18) "General Investment" [4]=> string(11) "Acquisition" [5]=> string(24) "Stock Research & Ratings" [6]=> string(8) "Verdicts" [7]=> string(12) "Stock Market" [8]=> string(21) "Intellectual Property" } } [6]=> array(7) { ["title_en"]=> string(38) "Market Trends Report 2023: Shohta Ueno" ["snippet_en"]=> string(80) "Ueno of Regeneron talks about strategy for the unitary patent and UPC litigation" ["url"]=> string(94) "https://www.managingip.com/article/2clb9fgrsvbx3uwszx2x2/market-trends-report-2023-shohta-ueno" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1b85bda3-9e73-4d4d-b70f-4b038b46c130" ["source"]=> string(14) "managingip.com" ["publication_date"]=> string(10) "2023-12-18" ["categories"]=> array(6) { [0]=> string(5) "R & D" [1]=> string(15) "Market Movement" [2]=> string(21) "Competitive Behaviour" [3]=> string(5) "Legal" [4]=> string(10) "Litigation" [5]=> string(21) "Intellectual Property" } } [7]=> array(7) { ["title_en"]=> string(70) "How Is The Market Feeling About Regeneron Pharmaceuticals? By Benzinga" ["snippet_en"]=> string(58) "How Is The Market Feeling About Regeneron Pharmaceuticals?" ["url"]=> string(113) "https://uk.investing.com/news/stock-market-news/how-is-the-market-feeling-about-regeneron-pharmaceuticals-3240453" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-11-16" ["categories"]=> array(4) { [0]=> string(10) "New Market" [1]=> string(21) "Competitive Behaviour" [2]=> string(5) "R & D" [3]=> string(15) "Market Movement" } } [8]=> array(7) { ["title_en"]=> string(101) "Regeneron to sell COVID-19 prophylactic antibody at internationally comparable price By Investing.com" ["snippet_en"]=> string(84) "Regeneron to sell COVID-19 prophylactic antibody at internationally comparable price" ["url"]=> string(143) "https://ph.investing.com/news/stock-market-news/regeneron-to-sell-covid19-prophylactic-antibody-at-internationally-comparable-price-93CH-983575" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-09-14" ["categories"]=> array(2) { [0]=> string(21) "Competitive Behaviour" [1]=> string(8) "Epidemic" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(265) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(117) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(62) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(60) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(44) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(21) } } } c469a-us-regeneron-pharmaceuticals-inc